	US 11,970,527 B2
	*Antibody directed against S. aureus* clumping factor A (ClfA)**
Christine Tkaczyk, Gaithersburg, MD (US); Bret Sellman, Gaithersburg, MD (US); Martin Borrok, III, Gaithersburg, MD (US); Davide Corti, Bellinzona (CH); and Andrea Minola, Bellinzona (CH)
Assigned to MedImmune, LLC, Gaithersburg, MD (US); and Humabs BioMed SA, Bellinzona (CH)
Filed by MedImmune, LLC, Gaithersburg, MD (US); and Humabs BioMed SA, Bellinzona (CH)
Filed on Sep. 23, 2021, as Appl. No. 17/483,162.
Application 17/483,162 is a division of application No. 16/521,223, filed on Jul. 24, 2019, granted, now 11,155,606.
Claims priority of provisional application 62/702,762, filed on Jul. 24, 2018.
Prior Publication US 2022/0073595 A1, Mar. 10, 2022
Int. Cl. C07K 16/12 (2006.01)

CPC C07K 16/1271 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01)]

15 Claims

1. A composition comprising (i) an antibody or antigen-binding fragment thereof that specifically binds to a Staphylococcus aureus (S. aureus) ClfA protein wherein said antibody or antigen-binding fragment comprises (1) a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:13, (2) a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:14, and (3) a heavy chain constant domain comprising the amino acid sequence of CSYHLC (SEQ ID NO: 21); and (ii) an antibody or antigen-binding fragment that specifically binds to an S. aureus alpha toxin (AT) protein.